The Experts below are selected from a list of 417 Experts worldwide ranked by ideXlab platform
Hitoshi Suzuki - One of the best experts on this subject based on the ideXlab platform.
-
Brief Report
2015Co-Authors: Yukihiko Kawasaki, Mitsuaki Hosoya, Schogo Kobayashi, Shinichirou Ohara, Noriko Onishi, Ai Takahashi, Masato Isome, Hitoshi SuzukiAbstract:Oral Mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrom
-
efficacy of single dose of oral Mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome
Journal of Nephrology, 2007Co-Authors: Yukihiko Kawasaki, Masato Isome, Hitoshi Suzuki, Junzo Suzuki, Kei Takano, Kazuhide Suyama, Hiroyuki Kanno, Tomoo Fujiki, Mitsuaki HosoyaAbstract:We assessed the efficacy of a single dose of oral Mizoribine (MZB) pulse therapy two times per week for children with frequently relapsing nephrotic syndrome (FRNS). Eleven children with FRNS in remission were treated with oral MZB pulse therapy (daily dose 6 mg/kg; maximum total dose 300 mg). We compared their clinical manifestations before and after oral MZB pulse therapy and examined the changes in serum MZB concentration in each patient on the days when MZB was administered. Eight patients had no subsequent relapses (responders), and prednisolone could be discontinued. Although 2 of the other 3 patients (nonresponders) had one relapse and the remaining patient had two relapses, both the dosages of prednisolone and frequency of relapse after oral MZB pulse therapy were significantly lower than before oral MZB pulse therapy. The peak blood concentration and AUC0-4 of MZB in the responders were higher than in the nonresponders. None of patients had severe adverse effects, such as uricacidemia, leukopenia, liver dysfunction or alopecia. Oral Mizoribine pulse therapy consisting of a single dose two days a week may be effective and safe in some FRNS patients.
-
oral Mizoribine pulse therapy for patients with steroid resistant and frequently relapsing steroid dependent nephrotic syndrome
Nephrology Dialysis Transplantation, 2005Co-Authors: Yukihiko Kawasaki, Mitsuaki Hosoya, Schogo Kobayashi, Shinichirou Ohara, Noriko Onishi, Ai Takahashi, Masato Isome, Hitoshi SuzukiAbstract:Background. We investigated the efficacy of oral Mizoribine pulse therapy (Mizoribine-pulse) for cyclosporin (CyA)-dependent, steroid-resistant nephrotic syndrome (SRNS) and frequently relapsing, steroiddependent nephrotic syndrome (FR-SDNS). Methods. One child with CyA-dependent SRNS and eight children with CyA-dependent FR-SDNS were treated with Mizoribine-pulse (daily dose: 10 mg/kg; maximum total dose 500 mg). We compared clinical manifestations before and after Mizoribine-pulse, and studied the changes in serum Mizoribine concentration in each patient on days when Mizoribine was administered. Results. Four patients had no subsequent relapses (responders). Two of the four responders discontinued prednisolone and CyA, the other two discontinued CyA. Although each of the five other patients (nonresponders) experienced single subsequent relapses, the dosages of prednisolone and CyA after Mizoribinepulse were decreased significantly compared with before Mizoribine-pulse. The peak blood concentration of Mizoribine in the responders was higher than in the non-responders (3.6±0.9 vs 1.8±0.4mg/ml). Conclusions. Mizoribine-pulse may be effective for some patients with CyA-dependent SRNS and FR-SDNS.
-
efficacy of multidrug therapy combined with Mizoribine in children with diffuse iga nephropathy in comparison with multidrug therapy without Mizoribine and with methylprednisolone pulse therapy
American Journal of Nephrology, 2004Co-Authors: Yukihiko Kawasaki, Mitsuaki Hosoya, Noriko Onishi, Ai Takahashi, Masato Isome, Junzo Suzuki, Ruriko Nozawa, Hitoshi SuzukiAbstract:Aim: To evaluate the efficacy of prednisolone, warfarin, and dipyridamole therapy combined with Mizoribine (PWDM) in the treatment of diffuse immunoglobulin A (IgA) nephropathy in c
-
efficacy of prednisolone and Mizoribine therapy for diffuse iga nephropathy
American Journal of Nephrology, 2004Co-Authors: Yukihiko Kawasaki, Junzo Suzuki, Ruriko Nozawa, Nobuko Sakai, Shigehiko Etoh, Hiromitch Murai, Hitoshi SuzukiAbstract:Objective: There have been only a few studies concerning oral prednisolone and Mizoribine therapy for diffuse IgA nephritis (IgAN). We evaluated the efficacy of prednisolone and miz
Yukihiko Kawasaki - One of the best experts on this subject based on the ideXlab platform.
-
Brief Report
2015Co-Authors: Yukihiko Kawasaki, Mitsuaki Hosoya, Schogo Kobayashi, Shinichirou Ohara, Noriko Onishi, Ai Takahashi, Masato Isome, Hitoshi SuzukiAbstract:Oral Mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrom
-
efficacy of single dose of oral Mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome
Journal of Nephrology, 2007Co-Authors: Yukihiko Kawasaki, Masato Isome, Hitoshi Suzuki, Junzo Suzuki, Kei Takano, Kazuhide Suyama, Hiroyuki Kanno, Tomoo Fujiki, Mitsuaki HosoyaAbstract:We assessed the efficacy of a single dose of oral Mizoribine (MZB) pulse therapy two times per week for children with frequently relapsing nephrotic syndrome (FRNS). Eleven children with FRNS in remission were treated with oral MZB pulse therapy (daily dose 6 mg/kg; maximum total dose 300 mg). We compared their clinical manifestations before and after oral MZB pulse therapy and examined the changes in serum MZB concentration in each patient on the days when MZB was administered. Eight patients had no subsequent relapses (responders), and prednisolone could be discontinued. Although 2 of the other 3 patients (nonresponders) had one relapse and the remaining patient had two relapses, both the dosages of prednisolone and frequency of relapse after oral MZB pulse therapy were significantly lower than before oral MZB pulse therapy. The peak blood concentration and AUC0-4 of MZB in the responders were higher than in the nonresponders. None of patients had severe adverse effects, such as uricacidemia, leukopenia, liver dysfunction or alopecia. Oral Mizoribine pulse therapy consisting of a single dose two days a week may be effective and safe in some FRNS patients.
-
oral Mizoribine pulse therapy for patients with steroid resistant and frequently relapsing steroid dependent nephrotic syndrome
Nephrology Dialysis Transplantation, 2005Co-Authors: Yukihiko Kawasaki, Mitsuaki Hosoya, Schogo Kobayashi, Shinichirou Ohara, Noriko Onishi, Ai Takahashi, Masato Isome, Hitoshi SuzukiAbstract:Background. We investigated the efficacy of oral Mizoribine pulse therapy (Mizoribine-pulse) for cyclosporin (CyA)-dependent, steroid-resistant nephrotic syndrome (SRNS) and frequently relapsing, steroiddependent nephrotic syndrome (FR-SDNS). Methods. One child with CyA-dependent SRNS and eight children with CyA-dependent FR-SDNS were treated with Mizoribine-pulse (daily dose: 10 mg/kg; maximum total dose 500 mg). We compared clinical manifestations before and after Mizoribine-pulse, and studied the changes in serum Mizoribine concentration in each patient on days when Mizoribine was administered. Results. Four patients had no subsequent relapses (responders). Two of the four responders discontinued prednisolone and CyA, the other two discontinued CyA. Although each of the five other patients (nonresponders) experienced single subsequent relapses, the dosages of prednisolone and CyA after Mizoribinepulse were decreased significantly compared with before Mizoribine-pulse. The peak blood concentration of Mizoribine in the responders was higher than in the non-responders (3.6±0.9 vs 1.8±0.4mg/ml). Conclusions. Mizoribine-pulse may be effective for some patients with CyA-dependent SRNS and FR-SDNS.
-
efficacy of multidrug therapy combined with Mizoribine in children with diffuse iga nephropathy in comparison with multidrug therapy without Mizoribine and with methylprednisolone pulse therapy
American Journal of Nephrology, 2004Co-Authors: Yukihiko Kawasaki, Mitsuaki Hosoya, Noriko Onishi, Ai Takahashi, Masato Isome, Junzo Suzuki, Ruriko Nozawa, Hitoshi SuzukiAbstract:Aim: To evaluate the efficacy of prednisolone, warfarin, and dipyridamole therapy combined with Mizoribine (PWDM) in the treatment of diffuse immunoglobulin A (IgA) nephropathy in c
-
efficacy of prednisolone and Mizoribine therapy for diffuse iga nephropathy
American Journal of Nephrology, 2004Co-Authors: Yukihiko Kawasaki, Junzo Suzuki, Ruriko Nozawa, Nobuko Sakai, Shigehiko Etoh, Hiromitch Murai, Hitoshi SuzukiAbstract:Objective: There have been only a few studies concerning oral prednisolone and Mizoribine therapy for diffuse IgA nephritis (IgAN). We evaluated the efficacy of prednisolone and miz
Takao Masaki - One of the best experts on this subject based on the ideXlab platform.
-
Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase 1 expression in aldosterone salt treated rats
PLOS ONE, 2014Co-Authors: Toshiki Doi, Shigehiro Doi, Ayumu Nakashima, Nobuoki Kohno, Toshinori Ueno, Yukio Yokoyama, Takao MasakiAbstract:Aldosterone-salt treatment induces not only hypertension but also extensive inflammation that contributes to fibrosis in the rat kidney. However, the mechanism underlying aldosterone-salt-induced renal inflammation remains unclear. Pyroptosis has recently been identified as a new type of cell death that is accompanied by the activation of inflammatory cytokines. We hypothesized that aldosterone-salt treatment could induce inflammation through pyroptosis and that Mizoribine, an effective immunosuppressant, would ameliorate the renal inflammation that would otherwise cause renal fibrosis. Ten days after recovery from left uninephrectomy, rats were given drinking water with 1% sodium chloride. The animals were divided into three groups (n = 7 per group): (1) vehicle infusion group, (2) aldosterone infusion group, or (3) aldosterone infusion plus oral Mizoribine group. Aldosterone-salt treatment increased the expression of the nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain containing 3 and caspase-1, and also increased the number of terminal deoxynucleotidyl transferase dUTP nick end labeling-positive cells. However, the oral administration of Mizoribine attenuated these alterations. Furthermore, Mizoribine inhibited hypertension and renal fibrosis, and also attenuated the aldosterone-induced expression of serum/glucocorticoid-regulated kinase and α epithelial sodium channel. These results suggest that caspase-1 activation plays an important role in the development of inflammation induced by aldosterone-salt treatment and that it functions as an anti-inflammatory strategy that protects against renal injury and hypertension.
-
Mizoribine ameliorates aldosterone-induced hypertension.
2014Co-Authors: Toshiki Doi, Shigehiro Doi, Ayumu Nakashima, Nobuoki Kohno, Toshinori Ueno, Yukio Yokoyama, Takao MasakiAbstract:Following infusion of aldosterone (ALD), hypertension developed over time. In contrast, Mizoribine (MZR) attenuated the degree of hypertension caused by ALD. Values are presented as mean ± SEM. *P
-
Mizoribine attenuates histological aldosterone-induced renal damage.
2014Co-Authors: Toshiki Doi, Shigehiro Doi, Ayumu Nakashima, Nobuoki Kohno, Toshinori Ueno, Yukio Yokoyama, Takao MasakiAbstract:Aldosterone (ALD) induced severe glomerular and tubulointerstitial injury, whereas Mizoribine (MZR) markedly attenuated the injury. (A) Representative photomicrographs of glomeruli and tubulointerstitial areas with periodic acid-Schiff staining. (B) Graphs show the quantification of glomeruli and tubulointerstitial injury. Values are presented as mean ± SEM. *P
-
Mizoribine suppresses the renal expression of genes for various aldosterone-induced pro-inflammatory cytokines.
2014Co-Authors: Toshiki Doi, Shigehiro Doi, Ayumu Nakashima, Nobuoki Kohno, Toshinori Ueno, Yukio Yokoyama, Takao MasakiAbstract:Aldosterone (ALD) increased the renal cortical expression of genes for interferon (IFN)-γ, tumor necrosis factor (TNF)-α, monocyte chemotactic protein (MCP)-1, and interleukin (IL)-1β, against that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In contrast, the expression of these genes was suppressed by Mizoribine (MZR). Values are presented as mean ± SEM. *P
-
Mizoribine suppresses aldosterone-induced renal inflammation.
2014Co-Authors: Toshiki Doi, Shigehiro Doi, Ayumu Nakashima, Nobuoki Kohno, Toshinori Ueno, Yukio Yokoyama, Takao MasakiAbstract:Aldosterone (ALD) induced considerable T lymphocyte and macrophage infiltration in the rat kidneys, whereas the infiltration was suppressed by Mizoribine (MZR). (A) Representative photomicrographs of renal T lymphocyte infiltration (CD3 staining) and macrophage infiltration (CD68 staining). (B) Graphs show the quantification of CD3-positive and CD68-positive cells. Values are presented as mean ± SEM. *P
Mitsuaki Hosoya - One of the best experts on this subject based on the ideXlab platform.
-
Brief Report
2015Co-Authors: Yukihiko Kawasaki, Mitsuaki Hosoya, Schogo Kobayashi, Shinichirou Ohara, Noriko Onishi, Ai Takahashi, Masato Isome, Hitoshi SuzukiAbstract:Oral Mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrom
-
efficacy of single dose of oral Mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome
Journal of Nephrology, 2007Co-Authors: Yukihiko Kawasaki, Masato Isome, Hitoshi Suzuki, Junzo Suzuki, Kei Takano, Kazuhide Suyama, Hiroyuki Kanno, Tomoo Fujiki, Mitsuaki HosoyaAbstract:We assessed the efficacy of a single dose of oral Mizoribine (MZB) pulse therapy two times per week for children with frequently relapsing nephrotic syndrome (FRNS). Eleven children with FRNS in remission were treated with oral MZB pulse therapy (daily dose 6 mg/kg; maximum total dose 300 mg). We compared their clinical manifestations before and after oral MZB pulse therapy and examined the changes in serum MZB concentration in each patient on the days when MZB was administered. Eight patients had no subsequent relapses (responders), and prednisolone could be discontinued. Although 2 of the other 3 patients (nonresponders) had one relapse and the remaining patient had two relapses, both the dosages of prednisolone and frequency of relapse after oral MZB pulse therapy were significantly lower than before oral MZB pulse therapy. The peak blood concentration and AUC0-4 of MZB in the responders were higher than in the nonresponders. None of patients had severe adverse effects, such as uricacidemia, leukopenia, liver dysfunction or alopecia. Oral Mizoribine pulse therapy consisting of a single dose two days a week may be effective and safe in some FRNS patients.
-
oral Mizoribine pulse therapy for patients with steroid resistant and frequently relapsing steroid dependent nephrotic syndrome
Nephrology Dialysis Transplantation, 2005Co-Authors: Yukihiko Kawasaki, Mitsuaki Hosoya, Schogo Kobayashi, Shinichirou Ohara, Noriko Onishi, Ai Takahashi, Masato Isome, Hitoshi SuzukiAbstract:Background. We investigated the efficacy of oral Mizoribine pulse therapy (Mizoribine-pulse) for cyclosporin (CyA)-dependent, steroid-resistant nephrotic syndrome (SRNS) and frequently relapsing, steroiddependent nephrotic syndrome (FR-SDNS). Methods. One child with CyA-dependent SRNS and eight children with CyA-dependent FR-SDNS were treated with Mizoribine-pulse (daily dose: 10 mg/kg; maximum total dose 500 mg). We compared clinical manifestations before and after Mizoribine-pulse, and studied the changes in serum Mizoribine concentration in each patient on days when Mizoribine was administered. Results. Four patients had no subsequent relapses (responders). Two of the four responders discontinued prednisolone and CyA, the other two discontinued CyA. Although each of the five other patients (nonresponders) experienced single subsequent relapses, the dosages of prednisolone and CyA after Mizoribinepulse were decreased significantly compared with before Mizoribine-pulse. The peak blood concentration of Mizoribine in the responders was higher than in the non-responders (3.6±0.9 vs 1.8±0.4mg/ml). Conclusions. Mizoribine-pulse may be effective for some patients with CyA-dependent SRNS and FR-SDNS.
-
efficacy of multidrug therapy combined with Mizoribine in children with diffuse iga nephropathy in comparison with multidrug therapy without Mizoribine and with methylprednisolone pulse therapy
American Journal of Nephrology, 2004Co-Authors: Yukihiko Kawasaki, Mitsuaki Hosoya, Noriko Onishi, Ai Takahashi, Masato Isome, Junzo Suzuki, Ruriko Nozawa, Hitoshi SuzukiAbstract:Aim: To evaluate the efficacy of prednisolone, warfarin, and dipyridamole therapy combined with Mizoribine (PWDM) in the treatment of diffuse immunoglobulin A (IgA) nephropathy in c
Masato Isome - One of the best experts on this subject based on the ideXlab platform.
-
Brief Report
2015Co-Authors: Yukihiko Kawasaki, Mitsuaki Hosoya, Schogo Kobayashi, Shinichirou Ohara, Noriko Onishi, Ai Takahashi, Masato Isome, Hitoshi SuzukiAbstract:Oral Mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrom
-
efficacy of single dose of oral Mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome
Journal of Nephrology, 2007Co-Authors: Yukihiko Kawasaki, Masato Isome, Hitoshi Suzuki, Junzo Suzuki, Kei Takano, Kazuhide Suyama, Hiroyuki Kanno, Tomoo Fujiki, Mitsuaki HosoyaAbstract:We assessed the efficacy of a single dose of oral Mizoribine (MZB) pulse therapy two times per week for children with frequently relapsing nephrotic syndrome (FRNS). Eleven children with FRNS in remission were treated with oral MZB pulse therapy (daily dose 6 mg/kg; maximum total dose 300 mg). We compared their clinical manifestations before and after oral MZB pulse therapy and examined the changes in serum MZB concentration in each patient on the days when MZB was administered. Eight patients had no subsequent relapses (responders), and prednisolone could be discontinued. Although 2 of the other 3 patients (nonresponders) had one relapse and the remaining patient had two relapses, both the dosages of prednisolone and frequency of relapse after oral MZB pulse therapy were significantly lower than before oral MZB pulse therapy. The peak blood concentration and AUC0-4 of MZB in the responders were higher than in the nonresponders. None of patients had severe adverse effects, such as uricacidemia, leukopenia, liver dysfunction or alopecia. Oral Mizoribine pulse therapy consisting of a single dose two days a week may be effective and safe in some FRNS patients.
-
oral Mizoribine pulse therapy for patients with steroid resistant and frequently relapsing steroid dependent nephrotic syndrome
Nephrology Dialysis Transplantation, 2005Co-Authors: Yukihiko Kawasaki, Mitsuaki Hosoya, Schogo Kobayashi, Shinichirou Ohara, Noriko Onishi, Ai Takahashi, Masato Isome, Hitoshi SuzukiAbstract:Background. We investigated the efficacy of oral Mizoribine pulse therapy (Mizoribine-pulse) for cyclosporin (CyA)-dependent, steroid-resistant nephrotic syndrome (SRNS) and frequently relapsing, steroiddependent nephrotic syndrome (FR-SDNS). Methods. One child with CyA-dependent SRNS and eight children with CyA-dependent FR-SDNS were treated with Mizoribine-pulse (daily dose: 10 mg/kg; maximum total dose 500 mg). We compared clinical manifestations before and after Mizoribine-pulse, and studied the changes in serum Mizoribine concentration in each patient on days when Mizoribine was administered. Results. Four patients had no subsequent relapses (responders). Two of the four responders discontinued prednisolone and CyA, the other two discontinued CyA. Although each of the five other patients (nonresponders) experienced single subsequent relapses, the dosages of prednisolone and CyA after Mizoribinepulse were decreased significantly compared with before Mizoribine-pulse. The peak blood concentration of Mizoribine in the responders was higher than in the non-responders (3.6±0.9 vs 1.8±0.4mg/ml). Conclusions. Mizoribine-pulse may be effective for some patients with CyA-dependent SRNS and FR-SDNS.
-
efficacy of multidrug therapy combined with Mizoribine in children with diffuse iga nephropathy in comparison with multidrug therapy without Mizoribine and with methylprednisolone pulse therapy
American Journal of Nephrology, 2004Co-Authors: Yukihiko Kawasaki, Mitsuaki Hosoya, Noriko Onishi, Ai Takahashi, Masato Isome, Junzo Suzuki, Ruriko Nozawa, Hitoshi SuzukiAbstract:Aim: To evaluate the efficacy of prednisolone, warfarin, and dipyridamole therapy combined with Mizoribine (PWDM) in the treatment of diffuse immunoglobulin A (IgA) nephropathy in c